MX392000B - Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer. - Google Patents

Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer.

Info

Publication number
MX392000B
MX392000B MX2019009351A MX2019009351A MX392000B MX 392000 B MX392000 B MX 392000B MX 2019009351 A MX2019009351 A MX 2019009351A MX 2019009351 A MX2019009351 A MX 2019009351A MX 392000 B MX392000 B MX 392000B
Authority
MX
Mexico
Prior art keywords
heteroarylsulfonyl
sup
cancer treatment
substituted pyridines
compounds
Prior art date
Application number
MX2019009351A
Other languages
English (en)
Other versions
MX2019009351A (es
Inventor
Benjamin Pelcman
Edgars Suna
Martins Priede
William Stafford
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MX2019009351A publication Critical patent/MX2019009351A/es
Publication of MX392000B publication Critical patent/MX392000B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos de la Fórmula I (I) (ver formula I) o sales aceptables desde el punto de vista farmacéutico de estos, en donde L, 10 R1, R2, R3 y X tienen significados proporcionados en la descripción, en donde los compuestos son útiles en el tratamiento de tipos de cáncer.
MX2019009351A 2017-02-07 2018-02-07 Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer. MX392000B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455639P 2017-02-07 2017-02-07
US201762594799P 2017-12-05 2017-12-05
PCT/GB2018/050343 WO2018146469A1 (en) 2017-02-07 2018-02-07 Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2019009351A MX2019009351A (es) 2019-09-19
MX392000B true MX392000B (es) 2025-03-21

Family

ID=61226606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009351A MX392000B (es) 2017-02-07 2018-02-07 Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer.

Country Status (12)

Country Link
US (1) US11028067B2 (es)
EP (1) EP3580215A1 (es)
JP (1) JP2020507625A (es)
KR (1) KR20190115013A (es)
CN (1) CN110382486A (es)
AU (1) AU2018218519B2 (es)
BR (1) BR112019016223A2 (es)
CA (1) CA3051537A1 (es)
MA (1) MA47451A (es)
MX (1) MX392000B (es)
WO (1) WO2018146469A1 (es)
ZA (1) ZA201904967B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
AU2018218518B2 (en) 2017-02-07 2022-03-17 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
MX392900B (es) 2017-02-07 2025-03-24 Oblique Therapeutics Ab Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer
RU2020126540A (ru) * 2018-02-12 2022-03-14 Синда Фарма Аб Ингибиторы тиоредоксинредуктазы для применения для лечения рака
CA3113234A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE4643T1 (de) 1979-12-19 1983-09-15 Duphar International Research B.V Nitrothiophene, verfahren zur herstellung der verbindungen sowie fungizide und/oder bakterizide zusammensetzungen auf der basis dieser verbindungen.
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
DE3812177A1 (de) 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
DE19531148A1 (de) 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
AU6926596A (en) 1995-08-24 1997-03-19 Basf Aktiengesellschaft N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications
WO1998054139A1 (de) 1997-05-30 1998-12-03 Basf Aktiengesellschaft Verfahren zur herstellung substituierter thiopyridine
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
EP1019391A1 (en) 1997-10-02 2000-07-19 Merck & Co. Inc. Inhibitors of prenyl-protein transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
PT930302E (pt) 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003068744A1 (en) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CA2568451A1 (en) 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
EP1976495A2 (en) 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
US20100009973A1 (en) 2006-04-28 2010-01-14 Avexa Limited Integrase Inhibitors 3
US20090005422A1 (en) * 2006-05-22 2009-01-01 Thioredoxin Systems Ab Bacterial thioredoxin reductase inhibitors and methods for use thereof
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
US9421211B2 (en) * 2009-05-28 2016-08-23 President And Fellows Of Harvard College N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation
EP3205647B1 (en) 2009-08-17 2020-05-13 Memorial Sloan-Kettering Cancer Center 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders
WO2011099502A1 (ja) 2010-02-10 2011-08-18 公立大学法人横浜市立大学 神経選択的転写抑制因子NRSFに特異的に結合するmSin3B に結合する化合物の利用
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
CA2864356A1 (en) 2012-02-10 2013-08-15 The Board Of Regents Of The University Of Texas System Modulators of exchange proteins directly activated by camp (epacs)
US8946418B1 (en) 2013-07-10 2015-02-03 Boehringer Ingelheim International Gmbh Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
AU2018218518B2 (en) 2017-02-07 2022-03-17 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer
MX392900B (es) 2017-02-07 2025-03-24 Oblique Therapeutics Ab Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
RU2019128045A3 (es) 2021-03-09
MX2019009351A (es) 2019-09-19
AU2018218519A1 (en) 2019-08-15
AU2018218519B2 (en) 2021-08-05
JP2020507625A (ja) 2020-03-12
CA3051537A1 (en) 2018-08-16
EP3580215A1 (en) 2019-12-18
US20200223819A1 (en) 2020-07-16
BR112019016223A2 (pt) 2020-04-07
US11028067B2 (en) 2021-06-08
CN110382486A (zh) 2019-10-25
KR20190115013A (ko) 2019-10-10
ZA201904967B (en) 2023-12-20
WO2018146469A1 (en) 2018-08-16
RU2019128045A (ru) 2021-03-09
MA47451A (fr) 2019-12-18

Similar Documents

Publication Publication Date Title
MX392000B (es) Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer.
MX391999B (es) Piridinas y su uso en el tratamiento del cáncer.
MX389800B (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CY1123451T1 (el) Αγωνιστες τριαζολης του υποδοχεα αρj
MX390535B (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
MX392900B (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer
CL2019002895A1 (es) Inhibidores de pd-1/pd-l1.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
CY1121885T1 (el) Αντι-ογκικες ενωσεις
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
MX376639B (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer.
MX2018008362A (es) Derivados de quinolin-2-ona.
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
CL2022000522A1 (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
WO2017027357A8 (en) Pyridazinones and their use in the treatment of cancer
CY1124851T1 (el) Νεες ενωσεις
MX395659B (es) Compuestos triciclicos y su uso en el tratamiento del cancer